Invention Reference Number
Targeted radionuclide therapy (TRT) has emerged as a promising method for cancer treatment, leveraging Meitner-Auger Electron (MAE)-emitting radionuclides. Among these, Antimony-119 (119Sb) is particularly notable for its properties, making it suitable for both therapeutic and diagnostic applications. However, the clinical use of 119Sb has been limited by the lack of suitable bifunctional chelators, which are essential for stable radionuclide retention in vivo.
Description
This technology involves antimony chelates specifically designed for targeted Auger therapy and imaging diagnostics. The chelates utilize antimony (Sb(V)) radionuclides bound to a chelating ligand. These ligands include catechol and hydroxypyridinone (HOPO) groups, which can form stable complexes with Sb(V) in vivo. The technology allows for the attachment of biological targeting vectors, enabling precise delivery of the radionuclide to cancer cells.
Benefits
- Enhanced targeting: Provides specific targeting to cancer cells, reducing damage to surrounding healthy tissue.
- Dual functionality: Suitable for both therapeutic and diagnostic (theranostic) applications.
- Stability: Chelating ligands ensure the stability of antimony radionuclides in biological environments.
- Flexibility: Can be conjugated with various biological targeting vectors for diverse applications.
Applications and Industries
- Cancer treatment: Effective in targeting and destroying cancer cells with minimal side effects.
- Diagnostic imaging: Facilitates single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging.
- Theranostics: Combines therapy and diagnostics for a comprehensive approach to cancer treatment.
Contact
To learn more about this technology, email partnerships@ornl.gov or call 865-574-1051.
